Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
Business Wire•06/11/2026•16:00 ET
0
Key Highlights
- ➤Faeth will report topline Phase 2 PIK-201 endometrial cancer results November 9, 2026.
- ➤Virtual event starts 8:00 AM ET and includes principal investigator David Starks.
- ➤PIKTOR Phase 1b/2 breast cancer interim data is anticipated in 2027.
Expert Statements
David Starks, MD, MPH; Gynecologic Oncologist, Avera Cancer Institute
“David Starks, MD, MPH (Gynecologic Oncologist, Avera Cancer Institute), who will join company management to provide clinical perspectives on the unmet need and evolving treatment landscape in advanced endometrial cancer.”
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here .
Get started
Create a free account to read the full story.